# Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects

> **NCT02573155** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 134 (actual)

## Conditions studied

- Asthma (Part 1)
- COPD (Part 2)

## Interventions

- **DRUG:** Dose 1, AZD8871 50 μg (Part 1)
- **DRUG:** Dose 2, AZD8871 100 μg (Part 1)
- **DRUG:** Dose 3, AZD8871 300 μg (Part 1)
- **DRUG:** Dose 4, AZD8871 600 µg (Part 1)
- **DRUG:** Dose 5, AZD8871 1200 µg (Part 1)
- **DRUG:** Dose 6, AZD8871 1800 μg (Part 1)
- **DRUG:** Placebo, AZD8871 placebo (Part 1)
- **DRUG:** Treatment A, AZD8871 dose A (Part 2)
- **DRUG:** Treatment B, AZD8871 dose B (Part 2)
- **DRUG:** Treatment C, Indacaterol 150 μg (Part 2)
- **DRUG:** Treatment D, Tiotropium 18 μg (Part 2)

## Key facts

- **NCT ID:** NCT02573155
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2018-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02573155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02573155, "Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02573155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*